Biopharmaceutical company Acasti Pharma Inc. (ACST) announced Monday top-line results for the Primary Endpoint (triglyceride reduction at 12 and 26 weeks) from its 278 patient Phase 3 TRILOGY 2 study evaluating the efficacy, safety and tolerability of CaPre in patients with severe hypertriglyceridemia. The study did not meet its primary endpoint.
from RTT - Biotech https://ift.tt/2EGOoAn
via IFTTT
No comments:
Post a Comment